ClinicalTrials.gg

Program

Axitinib

Also written as “AG-013736”, “axitinib” and “OTX-TKI”.

Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.

Furthest: phase 3, since May 7, 200745 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer360 open or runningphase 3since May 7, 2007Oct 9, 2003none ahead
Ocular Therapeutix54 open or runningphase 3since Jan 12, 2024Jun 1, 2018Jan 8, 2027phase 3 · NCT06495918
Arog Pharmaceuticals10 open or runningphase 2since Oct 6, 2006Oct 6, 2006none ahead
Merck10 open or runningphase 3since Jul 29, 2016Jul 29, 2016none ahead
SFJ Pharma Ltd. II10 open or runningphase 3since May 11, 2012May 11, 2012none ahead
Strata Oncology10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: fortrea, Gilead Sciences and sfj-pharmaceuticals-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 31 studies since Oct 9, 2003.

  1. Nov 2, 2011Phase 1 study in Advanced Solid TumorsPfizer · NCT01469052 · 36 enrolled · United States
  2. May 11, 2012SFJ Pharma Ltd. II's first study: phase 3 study in Carcinoma, Renal CellNew to SFJ Pharma Ltd. IISFJ Pharma Ltd. II · NCT01599754 · 724 enrolled · United States, China, France and more
  3. Nov 26, 2013Phase 1 study in CarcinomaPfizer · NCT01999972 · 50 enrolled · United States, United Kingdom
  4. May 6, 2014Phase 1 study in Carcinoma, Renal CellPfizer · NCT02133742 · 52 enrolled · United States
  5. Jan 25, 2016Phase 3 study in Carcinoma, Renal CellPfizer · NCT02684006 · 886 enrolled · United States, Australia, Austria and more
  6. Jul 29, 2016Merck's first study: phase 3 study in Carcinoma, Renal CellNew to MerckMerck · NCT02853331 · 861 enrolled
  7. Aug 28, 2017Phase 1 study in Carcinoma, HepatocellularPfizer · NCT03289533 · 22 enrolled · Japan
  8. Feb 28, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03472560 · 61 enrolled · United States, Hungary, Italy and more
  9. Jun 1, 2018Ocular Therapeutix's first study: phase 1 study in Neovascular Age-related Macular DegenerationNew to Ocular TherapeutixOcular Therapeutix · NCT03630315 · 29 enrolled · Australia
  10. Oct 1, 2021Strata Oncology's first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
  11. Jan 5, 2023Phase 1 study in Non-proliferative Diabetic RetinopathyOcular Therapeutix · NCT05695417 · 21 enrolled · United States
  12. Jan 12, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationOcular Therapeutix · NCT06223958 · 344 enrolled · United States, Argentina, Puerto Rico
  13. Jul 3, 2024Phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918 · 825 enrolled · United States, Argentina, Australia and more
  14. Mar 31, 2026Phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132 · 850 planned · United States

Ahead

  1. Jan 8, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationOcular Therapeutix · NCT06495918
  2. Aug 1, 2030Primary completion: phase 3 study in Neovascular Age-Related Macular Degeneration (nAMD)Ocular Therapeutix · NCT07516132

TargetBeta

“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 45 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07516132Neovascular Age-Related Macular Degeneration (nAMD) · United States3RecruitingOcular TherapeutixAug 1, 2030850
NCT06495918Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more3Active, not recruitingOcular TherapeutixJan 8, 2027825
NCT06223958Neovascular Age-Related Macular Degeneration · United States, Argentina, Puerto Rico3Active, not recruitingOcular TherapeutixApr 29, 2026344
NCT05695417Non-proliferative Diabetic Retinopathy · United States1Active, not recruitingOcular TherapeutixJan 202421
NCT05097599Neoplasms · United States2TerminatedStrata OncologyJun 12, 202411
NCT03630315Neovascular Age-related Macular Degeneration · Australia1CompletedOcular TherapeutixJan 10, 202429
NCT03472560Carcinoma, Non-Small-Cell Lung · United States, Hungary, Italy and more2TerminatedPfizerFeb 9, 202361
NCT03289533Carcinoma, Hepatocellular · Japan1CompletedPfizerAug 27, 201922
NCT02853331Carcinoma, Renal Cell3CompletedMerckOct 18, 2018861
NCT02684006Carcinoma, Renal Cell · United States, Australia, Austria and more3CompletedPfizerAug 31, 2023886
NCT02133742Carcinoma, Renal Cell · United States1CompletedPfizerMar 31, 201752
NCT01999972Carcinoma · United States, United Kingdom1CompletedPfizerFeb 22, 201750
NCT01599754Carcinoma, Renal Cell · United States, China, France and more3TerminatedSFJ Pharma Ltd. IIOct 10, 2017724
NCT01469052Advanced Solid Tumors · United States1CompletedPfizerJul 200436
NCT01441388Carcinoma, Renal Cell1WithdrawnPfizerNov 20130
NCT01210495Carcinoma, Hepatocellular · United States, Belgium, China and more2CompletedPfizerMar 3, 2014224
NCT01020136Healthy Volunteer · Singapore1CompletedPfizerFeb 201042
NCT00920816Kidney Neoplasms · United States, Bosnia and Herzegovina, Bulgaria and more3CompletedPfizerJul 27, 2012492
NCT00919204Healthy Volunteers · China1CompletedPfizerAug 200914
NCT00918632Healthy Volunteers · Belgium1CompletedPfizerJul 200930
NCT00905814Healthy Volunteers · Singapore1CompletedPfizerSep 200960
NCT00842244Stomach Neoplasms · Japan, Korea, Republic of1CompletedPfizerDec 200922
NCT00835978Carcinoma, Renal Cell · United States, Czechia, Germany and more2CompletedPfizerOct 2012213
NCT00828919Solid Tumors · United States, Czechia, France and more–CompletedPfizerAug 14, 202352
NCT00768755Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more2CompletedPfizerMar 2011180
NCT00735904Carcinoma · Poland, Romania, South Africa and more2CompletedPfizerNov 201138
NCT00726752Neoplasms · Japan1CompletedPfizerApr 20106
NCT00692341Hepatic Insufficiency · United States1CompletedPfizerOct 200824
NCT00678392Kidney Neoplasms · United States, Australia, Austria and more3CompletedPfizerAug 31, 2010723
NCT00615056Colorectal Neoplasms · United States, Canada, France and more2CompletedPfizerMar 2011171
NCT00600821Carcinoma, Non-Small-Cell Lung · United States, Czech Republic, France and more2CompletedPfizerApr 2011118
NCT00569946Carcinoma, Renal Cell · Japan2CompletedPfizerFeb 26, 201064
NCT00471146Carcinoma, Pancreatic Ductal · United States, Argentina, Australia and more3CompletedPfizerJan 2009630
NCT00460603Colorectal Neoplasms · United States2CompletedPfizerApr 2012187
NCT00454649Neoplasms · United States, Poland, Spain1CompletedPfizerAug 2009102
NCT00447005Carcinoma · Japan1CompletedPfizerAug 200912
NCT00389441Thyroid Neoplasms · United States, Canada, China and more2CompletedPfizerSep 201252
NCT00386555Carcinoma, Non-Small-Cell Lung2WithdrawnArog Pharmaceuticals0
NCT00282048Kidney Neoplasms · United States2CompletedPfizerFeb 200962
NCT00219557Pancreatic Neoplasms · United States, Belgium, Canada and more2CompletedPfizerMar 14, 2008111
NCT00094107Melanoma · United States, France2CompletedPfizerApr 200832
NCT00094094Lung Neoplasms · United States, Germany2CompletedPfizerJul 200732
NCT00094055Thyroid Neoplasms · United States2CompletedPfizerJan 200960
NCT00076024Breast Neoplasms · United States, Canada, Czech Republic and more2CompletedPfizerJan 2007174
NCT00071006Leukemia, Myeloid, Acute · United States2CompletedPfizerJul 200412

How it is read

Names in the registry

  • “AG-013736”, 23 entries
  • “axitinib”, 13 entries
  • “OTX-TKI”, 8 entries
  • “Axitinib (AG-013736)”, 8 entries
  • “AG-013736 (axitinib)”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.